Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $23.2B | $25.5B | $28.4B |
| Revenue growth | — | 9.8% | 11.5% |
| Gross profit | $5.88B | $6.98B | $7.52B |
| Gross margin | 25.3% | 27.3% | 26.4% |
| Operating income | $1.25B | $2.15B | $2.21B |
| Operating margin | 5.4% | 8.4% | 7.8% |
| Net income | $234M | $1.16B | $1.16B |
| Net margin | 1.0% | 4.6% | 4.1% |
| EPS (diluted) | — | — | -$0.01 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $1.69B | $1.77B | $1.74B |
| Capital expenditures | $275M | $354M | $447M |
| Free cash flow | $1.41B | $1.42B | $1.30B |
| Share buybacks | $0.00 | $20.0M | $33.0M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $1.58B | $199M | $1.94B |
| Total assets | — | $36.0B | $38.5B |
| Total liabilities | — | $19.5B | $19.2B |
| Long-term debt | — | $16.4B | $12.5B |
| Shareholders' equity | — | — | $10.7B |
| Retained earnings | — | — | -$7.00M |
| Shares (wtd avg diluted) | — | — | 810M |
Every figure is extracted from Medline Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.